Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of “Moderate Buy” by Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $52.80.

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Needham & Company LLC boosted their target price on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Barclays decreased their price target on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Truist Financial set a $55.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price objective (up previously from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $48.18 on Thursday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of 29.93 and a beta of 0.64. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $50.79. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. The company’s 50 day moving average is $47.37 and its 200 day moving average is $40.48.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.89 by $0.36. The business had revenue of $209.36 million for the quarter, compared to analysts’ expectations of $191.25 million. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business’s revenue for the quarter was down 18.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.61 EPS. On average, sell-side analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at $4,991,038.21. This trade represents a 14.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in COLL. Illinois Municipal Retirement Fund grew its stake in shares of Collegium Pharmaceutical by 1.6% during the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock worth $605,000 after acquiring an additional 278 shares during the last quarter. Vident Advisory LLC boosted its stake in Collegium Pharmaceutical by 1.9% in the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after purchasing an additional 281 shares in the last quarter. GAMMA Investing LLC boosted its stake in Collegium Pharmaceutical by 9.6% in the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 285 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 318 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.